Defining the Maximum Tolerated Dose: Investigator, Academic, Industry and Regulatory Perspectives
- 1 September 1997
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 37 (9) , 767-783
- https://doi.org/10.1002/j.1552-4604.1997.tb05624.x
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Concept of bridging studies and ethical concernsEuropean Journal of Clinical Pharmacology, 1996
- Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's diseaseLife Sciences, 1996
- Scientific and ethical concerns in clinical trials in Alzheimer's patients: the bridging studyEuropean Journal of Clinical Pharmacology, 1995
- A “bridging” (safety/tolerance) study of Besipirdine Hydrochloride in patients with Alzheimer's diseaseLife Sciences, 1995
- The Safety and Tolerance of Xanomeline Tartrate in Patients with Alzheimer's DiseaseThe Journal of Clinical Pharmacology, 1995
- Safety and tolerability of CI-979 in patients with alzheimer's diseaseLife Sciences, 1995
- A multiple-dose safety trial of eptastigmine in Alzheimer's disease, with pharmacodynamic observations of red blood cell cholinesteraseLife Sciences, 1994
- Clinical Safety, Tolerance, and Plasma Levels of the Oral Anticholinesterase 1,2,3,4-Tetrahydro-9-aminoacridin-1-oL-maleate (HP 029) in Alzheimer's Disease: Preliminary FindingsThe Journal of Clinical Pharmacology, 1990
- Design of Phase I and II Clinical Trials in Cancer: A Statistician's ViewCancer Investigation, 1984
- Clinical trials in cancer chemotherapyCancer, 1977